Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Key Insights Significantly high institutional ownership implies Aquestive Therapeutics' stock price is sensitive ...

January 23, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, all ...

In a challenging market environment, Centrexion Therapeutics Corp stock has touched a 52-week low, with shares falling to $0.9. According to InvestingPro data, the stock shows significant volatility ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

ProQR Therapeutics (PRQR ... dynamics amid a flurry of earnings reports and economic data releases. In this context, penny stocks—often associated with smaller or newer companies—continue ...